New lung cancer drug trial halted early – what we know
NCT ID NCT05662670
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new drug called WJ13405 in 14 people with advanced non-small cell lung cancer that had stopped responding to other treatments. The goal was to check safety, side effects, and how well the drug worked. However, the trial was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- WJ13405 tablets
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced lung cancer that has stopped responding to other targeted therapies.
- What could go wrong
- This was a very early, small study that was terminated, so we don't have enough data to know if it's safe or effective. Many early-stage cancer drugs never make it to approval.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.